Research integrity and pharmaceutical industry sponsorship

Peter C Gøtzsche
Med J Aust 2005; 182 (11): . || doi: 10.5694/j.1326-5377.2005.tb06807.x
Published online: 6 June 2005

Trial registration, transparency and less reliance on industry trials are essential

Over the past 20 years, politicians, hospital administrators and university deans have encouraged academic researchers to increase their participation in projects sponsored by the pharmaceutical industry, and the industry’s share of biomedical research has increased dramatically in that time (from 32% to 62% in the United States).1 Increasingly, the wisdom of this development has been challenged.

  • Peter C Gøtzsche

  • Nordic Cochrane Centre, Copenhagen, Denmark.


Competing interests:

None identified.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.